Review





Similar Products

vax 8600 computer system  (Digital Equipment Corporation)
86
Digital Equipment Corporation vax 8600 computer system
Vax 8600 Computer System, supplied by Digital Equipment Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vax/us12622944-1754-13-10
Average 86 stars, based on 1 article reviews
vax 8600 computer system - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
fel o vax lv k iv  (Elanco Inc)
86
Elanco Inc fel o vax lv k iv
Fel O Vax Lv K Iv, supplied by Elanco Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vax/fel+iv+k+lv+o+vax/10__1177_slash_1098612x261450889-96-8-14
Average 86 stars, based on 1 article reviews
fel o vax lv k iv - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
mkras vax  (Agenus Inc)
86
Agenus Inc mkras vax
a Treatment schema for patients treated with <t>mKRAS-VAX,</t> a pool of 6 synthetic long mKRAS peptides in the adjuvant setting. Patients receive four doses of 0.3 mg peptide/dose with 5ug polyICLC during the priming phase followed by booster vaccines every 8 weeks. Ipilimumab (1 mg/kg) and Nivolumab (3 mg/kg) were given for the first four doses followed by Nivolumab (480 mg) maintenance doses every four weeks. Created in BioRender. Huff, A. ( https://BioRender.com/1vglal1 ) ( b ) Clinical event timeline for each patient enrolled and vaccinated. c IFNγ ELISPOT assay of PMBCs collected at baseline and post-vaccination time points after restimulation with vehicle only control (unstimulated) or 2ug/mL control peptide or individual mKRAS long peptides overnight. Statistics of IFNγ spot forming units detected after each mKRAS peptide stimulation relative to control peptide are shown in Supplementary Table . Data are shown as mean ( n = 3) and upper limit of SD.
Mkras Vax, supplied by Agenus Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vax/mkras+vax/pmc12891733-27-12-21
Average 86 stars, based on 1 article reviews
mkras vax - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
vaxine f vax spl 2305 05 mpla avanti g 699800p  (Croda International Plc)
96
Croda International Plc vaxine f vax spl 2305 05 mpla avanti g 699800p
a Treatment schema for patients treated with <t>mKRAS-VAX,</t> a pool of 6 synthetic long mKRAS peptides in the adjuvant setting. Patients receive four doses of 0.3 mg peptide/dose with 5ug polyICLC during the priming phase followed by booster vaccines every 8 weeks. Ipilimumab (1 mg/kg) and Nivolumab (3 mg/kg) were given for the first four doses followed by Nivolumab (480 mg) maintenance doses every four weeks. Created in BioRender. Huff, A. ( https://BioRender.com/1vglal1 ) ( b ) Clinical event timeline for each patient enrolled and vaccinated. c IFNγ ELISPOT assay of PMBCs collected at baseline and post-vaccination time points after restimulation with vehicle only control (unstimulated) or 2ug/mL control peptide or individual mKRAS long peptides overnight. Statistics of IFNγ spot forming units detected after each mKRAS peptide stimulation relative to control peptide are shown in Supplementary Table . Data are shown as mean ( n = 3) and upper limit of SD.
Vaxine F Vax Spl 2305 05 Mpla Avanti G 699800p, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vax/MPLA/pmc12852915-3-24--1
Average 96 stars, based on 1 article reviews
vaxine f vax spl 2305 05 mpla avanti g 699800p - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
spike 398 vax primary series  (Moderna)
86
Moderna spike 398 vax primary series
a Treatment schema for patients treated with <t>mKRAS-VAX,</t> a pool of 6 synthetic long mKRAS peptides in the adjuvant setting. Patients receive four doses of 0.3 mg peptide/dose with 5ug polyICLC during the priming phase followed by booster vaccines every 8 weeks. Ipilimumab (1 mg/kg) and Nivolumab (3 mg/kg) were given for the first four doses followed by Nivolumab (480 mg) maintenance doses every four weeks. Created in BioRender. Huff, A. ( https://BioRender.com/1vglal1 ) ( b ) Clinical event timeline for each patient enrolled and vaccinated. c IFNγ ELISPOT assay of PMBCs collected at baseline and post-vaccination time points after restimulation with vehicle only control (unstimulated) or 2ug/mL control peptide or individual mKRAS long peptides overnight. Statistics of IFNγ spot forming units detected after each mKRAS peptide stimulation relative to control peptide are shown in Supplementary Table . Data are shown as mean ( n = 3) and upper limit of SD.
Spike 398 Vax Primary Series, supplied by Moderna, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vax/2+covid19+dose+primary+series/pm41513119-242-159-158
Average 86 stars, based on 1 article reviews
spike 398 vax primary series - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
fel o vax pct  (Zoetis)
86
Zoetis fel o vax pct
a Treatment schema for patients treated with <t>mKRAS-VAX,</t> a pool of 6 synthetic long mKRAS peptides in the adjuvant setting. Patients receive four doses of 0.3 mg peptide/dose with 5ug polyICLC during the priming phase followed by booster vaccines every 8 weeks. Ipilimumab (1 mg/kg) and Nivolumab (3 mg/kg) were given for the first four doses followed by Nivolumab (480 mg) maintenance doses every four weeks. Created in BioRender. Huff, A. ( https://BioRender.com/1vglal1 ) ( b ) Clinical event timeline for each patient enrolled and vaccinated. c IFNγ ELISPOT assay of PMBCs collected at baseline and post-vaccination time points after restimulation with vehicle only control (unstimulated) or 2ug/mL control peptide or individual mKRAS long peptides overnight. Statistics of IFNγ spot forming units detected after each mKRAS peptide stimulation relative to control peptide are shown in Supplementary Table . Data are shown as mean ( n = 3) and upper limit of SD.
Fel O Vax Pct, supplied by Zoetis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vax/fel+o+pct+vax/pmc12784829-165-6-12
Average 86 stars, based on 1 article reviews
fel o vax pct - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
q vax  (Seqirus Inc)
86
Seqirus Inc q vax
a Treatment schema for patients treated with <t>mKRAS-VAX,</t> a pool of 6 synthetic long mKRAS peptides in the adjuvant setting. Patients receive four doses of 0.3 mg peptide/dose with 5ug polyICLC during the priming phase followed by booster vaccines every 8 weeks. Ipilimumab (1 mg/kg) and Nivolumab (3 mg/kg) were given for the first four doses followed by Nivolumab (480 mg) maintenance doses every four weeks. Created in BioRender. Huff, A. ( https://BioRender.com/1vglal1 ) ( b ) Clinical event timeline for each patient enrolled and vaccinated. c IFNγ ELISPOT assay of PMBCs collected at baseline and post-vaccination time points after restimulation with vehicle only control (unstimulated) or 2ug/mL control peptide or individual mKRAS long peptides overnight. Statistics of IFNγ spot forming units detected after each mKRAS peptide stimulation relative to control peptide are shown in Supplementary Table . Data are shown as mean ( n = 3) and upper limit of SD.
Q Vax, supplied by Seqirus Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vax/q+vax/pmc12345007-139-0-35
Average 86 stars, based on 1 article reviews
q vax - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
q fever vaccine q vax  (Seqirus Inc)
86
Seqirus Inc q fever vaccine q vax
a Treatment schema for patients treated with <t>mKRAS-VAX,</t> a pool of 6 synthetic long mKRAS peptides in the adjuvant setting. Patients receive four doses of 0.3 mg peptide/dose with 5ug polyICLC during the priming phase followed by booster vaccines every 8 weeks. Ipilimumab (1 mg/kg) and Nivolumab (3 mg/kg) were given for the first four doses followed by Nivolumab (480 mg) maintenance doses every four weeks. Created in BioRender. Huff, A. ( https://BioRender.com/1vglal1 ) ( b ) Clinical event timeline for each patient enrolled and vaccinated. c IFNγ ELISPOT assay of PMBCs collected at baseline and post-vaccination time points after restimulation with vehicle only control (unstimulated) or 2ug/mL control peptide or individual mKRAS long peptides overnight. Statistics of IFNγ spot forming units detected after each mKRAS peptide stimulation relative to control peptide are shown in Supplementary Table . Data are shown as mean ( n = 3) and upper limit of SD.
Q Fever Vaccine Q Vax, supplied by Seqirus Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vax/fever+kit+q+skin+test/pmc12691656-97-9-0
Average 86 stars, based on 1 article reviews
q fever vaccine q vax - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
yf vax  (Sanofi)
86
Sanofi yf vax
a Treatment schema for patients treated with <t>mKRAS-VAX,</t> a pool of 6 synthetic long mKRAS peptides in the adjuvant setting. Patients receive four doses of 0.3 mg peptide/dose with 5ug polyICLC during the priming phase followed by booster vaccines every 8 weeks. Ipilimumab (1 mg/kg) and Nivolumab (3 mg/kg) were given for the first four doses followed by Nivolumab (480 mg) maintenance doses every four weeks. Created in BioRender. Huff, A. ( https://BioRender.com/1vglal1 ) ( b ) Clinical event timeline for each patient enrolled and vaccinated. c IFNγ ELISPOT assay of PMBCs collected at baseline and post-vaccination time points after restimulation with vehicle only control (unstimulated) or 2ug/mL control peptide or individual mKRAS long peptides overnight. Statistics of IFNγ spot forming units detected after each mKRAS peptide stimulation relative to control peptide are shown in Supplementary Table . Data are shown as mean ( n = 3) and upper limit of SD.
Yf Vax, supplied by Sanofi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vax/vax+yf/pmc12676263-25-8-9
Average 86 stars, based on 1 article reviews
yf vax - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
pfizer vax measles k  (Pfizer Inc)
86
Pfizer Inc pfizer vax measles k
a Treatment schema for patients treated with <t>mKRAS-VAX,</t> a pool of 6 synthetic long mKRAS peptides in the adjuvant setting. Patients receive four doses of 0.3 mg peptide/dose with 5ug polyICLC during the priming phase followed by booster vaccines every 8 weeks. Ipilimumab (1 mg/kg) and Nivolumab (3 mg/kg) were given for the first four doses followed by Nivolumab (480 mg) maintenance doses every four weeks. Created in BioRender. Huff, A. ( https://BioRender.com/1vglal1 ) ( b ) Clinical event timeline for each patient enrolled and vaccinated. c IFNγ ELISPOT assay of PMBCs collected at baseline and post-vaccination time points after restimulation with vehicle only control (unstimulated) or 2ug/mL control peptide or individual mKRAS long peptides overnight. Statistics of IFNγ spot forming units detected after each mKRAS peptide stimulation relative to control peptide are shown in Supplementary Table . Data are shown as mean ( n = 3) and upper limit of SD.
Pfizer Vax Measles K, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vax/k+measles+pfizer+vax/pm41246889-175-2-2
Average 86 stars, based on 1 article reviews
pfizer vax measles k - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

Image Search Results


a Treatment schema for patients treated with mKRAS-VAX, a pool of 6 synthetic long mKRAS peptides in the adjuvant setting. Patients receive four doses of 0.3 mg peptide/dose with 5ug polyICLC during the priming phase followed by booster vaccines every 8 weeks. Ipilimumab (1 mg/kg) and Nivolumab (3 mg/kg) were given for the first four doses followed by Nivolumab (480 mg) maintenance doses every four weeks. Created in BioRender. Huff, A. ( https://BioRender.com/1vglal1 ) ( b ) Clinical event timeline for each patient enrolled and vaccinated. c IFNγ ELISPOT assay of PMBCs collected at baseline and post-vaccination time points after restimulation with vehicle only control (unstimulated) or 2ug/mL control peptide or individual mKRAS long peptides overnight. Statistics of IFNγ spot forming units detected after each mKRAS peptide stimulation relative to control peptide are shown in Supplementary Table . Data are shown as mean ( n = 3) and upper limit of SD.

Journal: Nature Communications

Article Title: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial

doi: 10.1038/s41467-026-68324-4

Figure Lengend Snippet: a Treatment schema for patients treated with mKRAS-VAX, a pool of 6 synthetic long mKRAS peptides in the adjuvant setting. Patients receive four doses of 0.3 mg peptide/dose with 5ug polyICLC during the priming phase followed by booster vaccines every 8 weeks. Ipilimumab (1 mg/kg) and Nivolumab (3 mg/kg) were given for the first four doses followed by Nivolumab (480 mg) maintenance doses every four weeks. Created in BioRender. Huff, A. ( https://BioRender.com/1vglal1 ) ( b ) Clinical event timeline for each patient enrolled and vaccinated. c IFNγ ELISPOT assay of PMBCs collected at baseline and post-vaccination time points after restimulation with vehicle only control (unstimulated) or 2ug/mL control peptide or individual mKRAS long peptides overnight. Statistics of IFNγ spot forming units detected after each mKRAS peptide stimulation relative to control peptide are shown in Supplementary Table . Data are shown as mean ( n = 3) and upper limit of SD.

Article Snippet: In a first-in-human phase I clinical trial (ClinicalTrials.gov: NCT04117087 ), we tested mKRAS-VAX in combination with nivolumab (anti–PD-1 antibody) and ipilimumab (anti–CTLA–4 antibody) in patients with resected PDAC.

Techniques: Adjuvant, Vaccines, Enzyme-linked Immunospot, Control